Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA. Treatment patterns and health outcomes in platinum-refractory or platinum-resistant ovarian cancer: a retrospective medical record review. Int J Gynecol Cancer. 2018 May;20(4):738-48. doi: 10.1097/IGC.0000000000001222
Layton JB, Li D, Meier CR, Sharpless JL, Sturmer T, Brookhart MA. Injection testosterone and adverse cardiovascular events: a case-crossover analysis. Clin Endocrinol (Oxf). 2018 May;88(5):719-27. doi: 10.1111/cen.13574
Knoll S, Jochum D, Talbird S. Comparative cost benefit analysis of two new Pneumococcal Conjugate Vaccines (PHiD-CV and PCV-13). Klin Padiatr. 2010 Jun 1;222(Suppl 1):S51-2.
Alvarez-Pedrerol M, Ribas-Fito N, Garcia-Esteban R, Rodriguez A, Soriano D, Guxens M, Mendez M, Sunyer J. Iodine sources and iodine levels in pregnant women from an area without known iodine deficiency. Clin Endocrinol (Oxf). 2010 Jan;72(1):81-6. doi: 10.1111/j.1365-2265.2009.03588.x
Alverez SA, Bae-Jump V, Havrilesky LJ, Calingaert B, Clarke-Pearson ADL, Soper JT, Gehrig PA. Attitudes regarding the use of hematopoietic colony-stimulating factor utilization and maintenance of relative dose intensity among gynecologic oncologists. Int J Gynecol Cancer. 2009 Apr;19(3):447-54.
Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A. High expression of insulin-like growth factor binding protein–2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer. 2006 Jul 1;16(4):1529-35.
Wirén L, Whalley D, McKenna SP, Wilhelmsen L. Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by Rasch analysis. Clin Endocrinol (Oxf). 2000 Feb;52(2):143-52.
McKenna S, Doward LC. Measuring quality of life in adults with growth hormone deficiency. Clin Endocrinol (Oxf). 1996 Oct;45(4):507-8.